After careers in Pharma and MedTech, the co-founders were eager to drive innovation and help people rather than get slowed down by corporate structures. They joined Evoleen, an incubator partnering with health industry players, co-creating new ventures to accelerate innovation. After prototyping several digital health initiatives, they started the SIVA project in coordination with the global pharmaceutical company Bayer, which was developing a novel drug targeting refractory chronic cough. From the successful initial feasibility project findings, it became clear that the team was holding the keys to addressing many important unmet needs in the cough space. They co-founded SIVA Health and have been driving the vision of providing better lives for respiratory patients ever since.
 
After Bayer discontinued its refractory chronic cough drug development project, SIVA Health became fully independent and owns all generated IPs. Today, the team works with several leading global pharmaceutical companies to support their efforts to develop better treatment options for respiratory patients.